Summary of Significant Accounting Policies (Tables)

6 Months Ended

Jun. 30, 2026

Accounting Policies [Abstract]

Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash

The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the condensed consolidated balance sheets that sum to the total of the same amounts shown in the condensed consolidated statements of cash flows:


		Six Months Ended June 30,
		2026				2025
		(In thousands)
Cash and cash equivalents		$	59,915			$	44,771
Restricted cash			1,846				1,846
Total cash, cash equivalents, and restricted cash		$	61,761			$	46,617

Summary of Segment Profit or Loss Including Significant Segment Expenses

The table below is a summary of the segment profit or loss, including significant segment expenses (in thousands):


		Three Months Ended June 30,								Six Months Ended June 30,
		2026				2025				2026				2025
Collaboration revenue		$	3,320			$	7,874			$	4,366			$	11,548
Less:
Compensation and benefits			7,067				14,262				15,315				30,819
Lab expenses and outside research services			4,809				2,903				8,256				6,127
Clinical supply costs			3,028				3,873				4,407				6,947
Clinical trials			1,371				7,081				4,755				14,094
Support functions			6,123				7,701				12,423				15,987
Other segment expenses(a)			5,315				6,192				8,522				16,407
Total operating expenses			27,713				42,012				53,678				90,381
Loss from operations			(24,393	)			(34,138	)			(49,312	)			(78,833	)
Other income, net			1,533				3,614				3,522				7,838
Income tax			130				—				130				—
Segment and consolidated loss		$	(22,990	)		$	(30,524	)		$	(45,920	)		$	(70,995	)

(a) Other segment expenses include consultants & contractor expense, contra-R&D expense for GSK collaboration, depreciation expense, impairment loss, restructuring expense, and stock-based compensation expense.